Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Life > 2025 Vol. 3 > No. 2 > 100112
Next Article Previous Article
COMMENTARY   Open Access     Cite

Empowering immune responses against cancer by IL-21-driven T cell reprogramming

  • 1.

    Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

  • 2.

    Department of Chemical Engineering, Northwest University, Xi'an 710069, China

  • 3.

    School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou 325027, China

  • 4.

    Institute of Chemistry, University of Silesia in Katowice, Katowice 40-006, Poland

More Information
The Innovation Life  3(2),  https://doi.org/10.59717/j.xinn-life.2024.100127  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Tan R., Zhao J. and Shubhra Q.T.H. (2024). Eclipsing toxicity, enhancing efficacy: Clofazimine’s vanguard in the realm of anti-PD-1 and CTLA-4 immunotherapy. Research 7:0419. DOI:10.34133/research.0419

    View in Article CrossRef Google Scholar

    [2] Du Y., Liu L., Ma W., et al. (2023). The role of extratumoral and intratumoral microorganisms in cancer immunotherapy. The Innovation Life 1:100016. DOI:10.59717/j.xinn-life.2023.100016

    View in Article CrossRef Google Scholar

    [3] Zhang Z., Langenbach M., Sagar S., et al. (2024). Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells. Nat. Immunol. 26:92−104. DOI:10.1038/s41590-024-02027-0

    View in Article CrossRef Google Scholar

    [4] Zhu W., Zhang Z., Chen J., et al. (2024). A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal Transduct. Target. Ther. 9:101. DOI:10.1038/s41392-024-01792-6

    View in Article CrossRef Google Scholar Scopus

    [5] Shubhra Q.T.H., Feczkó T. and Cai, Q. (2024). Beyond the danger signal: RNA aggregates orchestrate immunotherapy. Trends Mol. Med. 30:702−704. DOI:10.1016/j.molmed.2024.05.018

    View in Article CrossRef Google Scholar Scopus

    • Cited by

  • Cite this article:

    Cai Q., Wen H., Musiol R., et al. (2025). Empowering immune responses against cancer by IL-21-driven T cell reprogramming. The Innovation Life 3:1001127. https://doi.org/10.59717/j.xinn-life.2024.100127
    Cai Q., Wen H., Musiol R., et al. (2025). Empowering immune responses against cancer by IL-21-driven T cell reprogramming. The Innovation Life 3:1001127. https://doi.org/10.59717/j.xinn-life.2024.100127

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(2306) PDF downloads(1385)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.